TXG

10X GENOMICS INC-CLASS A

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary

10X GENOMICS INC-CLASS A (TXG) is held as common stock by 8 tracked hedge-fund managers, with a combined reported value of ~$616.55M; the largest are Cathie Wood, Ken Griffin, Steven Cohen. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 2 new, 1 added, 5 trimmed. 1 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.

Attention · HighThis quarter · Cooling

Common-stock holders81 also report options

Congress trades1

Price$88.50vs quarter-end+130.83%

Sectors0

This quarter's moves

New2

Added1

Trimmed / sold5

Top holder

Cathie Wood

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Investor	Period	Value	Shares	% of portfolio	Action

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinCALL—

Value $5.76M— of portfolio150,2002026 Q2

Ken GriffinPUT—

Value $1.41M— of portfolio36,9002026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Ken GriffinCALL	2026 Q2	$5.76M	150,200	—	—
Ken GriffinPUT	2026 Q2	$1.41M	36,900	—	—

Insider Trading

Officers · directors · Form 4

Open-market purchases and sales (P/S)22

Adam Taich
Chief Financial Officer
Sell$2.02M
31,428 @ $64.31Traded 2026-09-09Filed 2026-09-11
Adam Taich
Chief Financial Officer
Sell$897.5K
13,754 @ $65.26Traded 2026-09-09Filed 2026-09-11
Adam Taich
Chief Financial Officer
Sell$76.8K
1,206 @ $63.68Traded 2026-09-09Filed 2026-09-11
John R Stuelpnagel
Director
Sell$425.3K
7,012 @ $60.66Traded 2026-09-03Filed 2026-09-08
John R Stuelpnagel
Director
Sell$423.2K
6,814 @ $62.11Traded 2026-09-03Filed 2026-09-08
John R Stuelpnagel
Director
Sell$386.5K
6,174 @ $62.61Traded 2026-09-03Filed 2026-09-08
Serge Saxonov
Chief Executive Officer
Sell$31.9K
492 @ $64.75Traded 2026-08-26Filed 2026-08-28
Serge Saxonov
Chief Executive Officer
Sell$220.6K
3,500 @ $63.02Traded 2026-08-26Filed 2026-08-28
Serge Saxonov
Chief Executive Officer
Sell$415.5K
6,494 @ $63.98Traded 2026-08-26Filed 2026-08-28
Adam Taich
Chief Financial Officer
Sell$1.08M
17,166 @ $63.02Traded 2026-08-24Filed 2026-08-26
Serge Saxonov
Chief Executive Officer
Sell$1.17M
18,545 @ $63.02Traded 2026-08-24Filed 2026-08-26
Shehnaaz Suliman
Director
Sell$105.3K
1,646 @ $63.97Traded 2026-08-24Filed 2026-08-26
Shehnaaz Suliman
Director
Sell$35.2K
561 @ $62.73Traded 2026-08-24Filed 2026-08-26
Benjamin J. Hindson
Title: President and Chief Scientific Officer
Sell$870.9K
13,818 @ $63.02Traded 2026-08-24Filed 2026-08-26
Sarah A. Teichmann
Director
Sell$302.4K
5,278 @ $57.29Traded 2026-08-13Filed 2026-08-17
Sarah A. Teichmann
Director
Sell$129.9K
2,273 @ $57.15Traded 2026-08-13Filed 2026-08-17
John R Stuelpnagel
Director
Sell$176.2K
3,000 @ $58.73Traded 2026-08-11Filed 2026-08-13
John R Stuelpnagel
Director
Sell$978.9K
17,000 @ $57.58Traded 2026-08-11Filed 2026-08-13
Serge Saxonov
Chief Executive Officer
Sell$60.1K
1,661 @ $36.16Traded 2026-06-22Filed 2026-06-24
Serge Saxonov
Chief Executive Officer
Sell$346.8K
9,821 @ $35.32Traded 2026-06-22Filed 2026-06-24
Serge Saxonov
Chief Executive Officer
Sell$283.9K
8,527 @ $33.29Traded 2026-06-22Filed 2026-06-24
Serge Saxonov
Chief Executive Officer
Sell$342.5K
9,991 @ $34.28Traded 2026-06-22Filed 2026-06-24

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

ARK ETF holdings

Cathie Wood · daily

ARK total shares held · drag to inspect

2026-09-29holds 6,217,747

ARKGweight in fund10.19%$221.72M
ARKKweight in fund3.84%$328.55M

ARK publishes full ETF holdings daily (SEC Rule 6c-11). Line shows ARK's total shares held over time (not price); markers are buy/sell days. Derived from public CSVs — research only, not investment advice.

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.